Anzeige
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
171 Leser
Artikel bewerten:
(0)

AMRI Names Michael Mulhern as Chief Executive Officer

Seasoned Healthcare Executive Tasked with Growing Global Contract Development and Manufacturing Organization

ALBANY, N.Y., Jan.4, 2018 /PRNewswire/ --AMRI, a global pharmaceutical contract research, development and manufacturing organization, today announced that Michael Mulhern has joined the company as chief executive officer, succeeding William S. Marth. Mr. Mulhern was previously chief executive officer of Sterigenics International, a leading global provider of contract sterilization, gamma technologies and medical isotopes. Mr. Marth will remain with the company in an advisory role. AMRI is a portfolio company of The Carlyle Group and GTCR.

AMRI

Stephen H. Wise, managing director and global head of healthcare for Carlyle, said, "Michael is a highly accomplished executive with a 30-year track record of value creation in the healthcare and distribution sectors. His role as a member of AMRI's board of directors, coupled with his experience leading three private equity-backed companies, will make this a smooth transition."

Dean Mihas, managing director and head of healthcare for GTCR, said, "We thank Bill for his years of successful leadership of AMRI. Since joining the board of directors in 2012 and becoming CEO in 2014, Bill has been instrumental in building AMRI into a leading contract research, development and manufacturing organization. We wish him success in his future endeavors."

Mr. Mulhern said, "I am excited to join AMRI and look forward to working with such a talented group of professionals around the world to make a great company even better. I believe a cohesive, integrated AMRI will better enable us to serve our global customers. Bill and his team have accomplished great things, and I look forward to leading AMRI through its next phase of growth."

Since 2002, Mr. Mulhern has been CEO of three companies backed by GTCR - Sterigenics International, Fairmont Food Group, and American Sanitary - where he established a track record of product development, operational excellence, quality customer service and global growth. He previously held roles at Baxter International and Alliant Foodservice. Mr. Mulhern earned his B.A. in economics from Pennsylvania State University.

About AMRI
AMRI, a global contract research and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life. With locations in North America, Europe and Asia, AMRI's team combines scientific expertise and market-leading technology to provide a complete suite of solutions in Discovery, Development, Analytical and Solid State Services, API Manufacturing and Drug Product. For more information about AMRI, visit https://www.amriglobal.com.

Logo - http://mma.prnewswire.com/media/550929/AMRI_Logo.jpg

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2018 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.